Literature DB >> 21172315

Visual abnormalities associated with enhanced optic nerve myelination.

Minzhong Yu1, S Priyadarshini Narayanan, Feng Wang, Emily Morse, Wendy B Macklin, Neal S Peachey.   

Abstract

Expression of the constitutively active serine/threonine kinase Akt in oligodendrocytes results in enhanced myelination in the CNS. Here, we have examined the effects of this Akt overexpression on optic nerve structure and on optic nerve function, assessed using the visual evoked potential (VEP). Transgenic mice have been generated with the Plp promoter driving expression of a modified form of Akt, in which aspartic acids are substituted for Thr308 and Ser473. These Plp-Akt-DD (Akt-DD) mice, and littermate controls, were studied at different ages. Optic nerves were examined anatomically at 2 and 6 months of age. At 2 months of age, optic nerves were substantially thicker in Akt-DD mice, reflecting an increase in myelination of optic nerve axons. By electron microscopy, myelin thickness was increased in Akt-DD optic nerve, with extended paranodal domains having excess paranodal loops, and the density of nodes of Ranvier was reduced, relative to control mice. We recorded VEPs in response to strobe flash ganzfeld stimuli presented after overnight dark- and light-adapted conditions at ages ranging from 1 to 10 months. It was possible to record a clear VEP from Akt-DD mice at all ages examined. At 1 month of age, VEP implicit times were somewhat shorter in Akt-DD transgenic mice than in control animals. Beyond 6months of age, VEP latencies were consistently delayed in Akt-DD transgenic mice. These abnormalities did not reflect an alteration in retinal function as there were no significant differences between ERGs obtained from control or Akt-DD transgenic mice. In young mice, the somewhat faster responses may reflect improved transmission due to increased myelination of optic nerve axons. In older mice, where the Akt-DD optic nerve is markedly thicker than control, it is remarkable that optic nerves continue to function.
Copyright © 2010 Elsevier B.V. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 21172315      PMCID: PMC4395475          DOI: 10.1016/j.brainres.2010.12.043

Source DB:  PubMed          Journal:  Brain Res        ISSN: 0006-8993            Impact factor:   3.252


  24 in total

1.  The visual evoked potential in the mouse--origins and response characteristics.

Authors:  W H Ridder; S Nusinowitz
Journal:  Vision Res       Date:  2005-10-20       Impact factor: 1.886

2.  Bace1 modulates myelination in the central and peripheral nervous system.

Authors:  Xiangyou Hu; Caitlin W Hicks; Wanxia He; Philip Wong; Wendy B Macklin; Bruce D Trapp; Riqiang Yan
Journal:  Nat Neurosci       Date:  2006-11-12       Impact factor: 24.884

3.  A comparative study of visual evoked potentials in optic neuritis and optic neuritis with multiple sclerosis.

Authors:  Pathanee Samsen; Wanicha L Chuenkongkaew; Patcharapim Masayaanon; Niphon Chirapapaisan; Ngamkae Ruangvaravate; Siriwan Loket
Journal:  J Med Assoc Thai       Date:  2007-02

4.  Increasing the diagnostic value of evoked potentials in multiple sclerosis by quantitative topographic analysis of multichannel recordings.

Authors:  Agustina M Lascano; Verena Brodbeck; Patrice H Lalive; Michel Chofflon; Margitta Seeck; Christoph M Michel
Journal:  J Clin Neurophysiol       Date:  2009-10       Impact factor: 2.177

5.  Flash visual evoked potentials in the hypomyelinated mutant mouse shiverer.

Authors:  Donna M Lehman; Joseph M Harrison
Journal:  Doc Ophthalmol       Date:  2002-01       Impact factor: 2.379

6.  Experimental optic neuritis induced by a demyelinating strain of mouse hepatitis virus.

Authors:  Kenneth S Shindler; Lawrence C Kenyon; Mahasweta Dutt; Susan T Hingley; Jayasri Das Sarma
Journal:  J Virol       Date:  2008-06-25       Impact factor: 5.103

7.  Response of a neuronal model of tuberous sclerosis to mammalian target of rapamycin (mTOR) inhibitors: effects on mTORC1 and Akt signaling lead to improved survival and function.

Authors:  Lynsey Meikle; Kristen Pollizzi; Anna Egnor; Ioannis Kramvis; Heidi Lane; Mustafa Sahin; David J Kwiatkowski
Journal:  J Neurosci       Date:  2008-05-21       Impact factor: 6.167

8.  Akt signals through the mammalian target of rapamycin pathway to regulate CNS myelination.

Authors:  S Priyadarshini Narayanan; Ana I Flores; Feng Wang; Wendy B Macklin
Journal:  J Neurosci       Date:  2009-05-27       Impact factor: 6.167

9.  Physiological deficits in the visual system of mice infected with Semliki Forest virus and their correlation with those seen in patients with demyelinating disease.

Authors:  K E Tremain; H Ikeda
Journal:  Brain       Date:  1983-12       Impact factor: 13.501

10.  Multimodality-evoked potential study of anti-aquaporin-4 antibody-positive and -negative multiple sclerosis patients.

Authors:  Akihiro Watanabe; Takuya Matsushita; Hikaru Doi; Takashi Matsuoka; Hiroshi Shigeto; Noriko Isobe; Yuji Kawano; Shozo Tobimatsu; Jun-ichi Kira
Journal:  J Neurol Sci       Date:  2009-04-01       Impact factor: 3.181

View more
  10 in total

Review 1.  Neuroglialpharmacology: myelination as a shared mechanism of action of psychotropic treatments.

Authors:  George Bartzokis
Journal:  Neuropharmacology       Date:  2012-01-28       Impact factor: 5.250

2.  Age-related changes in visual function in cystathionine-beta-synthase mutant mice, a model of hyperhomocysteinemia.

Authors:  Minzhong Yu; Gwen Sturgill-Short; Preethi Ganapathy; Amany Tawfik; Neal S Peachey; Sylvia B Smith
Journal:  Exp Eye Res       Date:  2011-12-16       Impact factor: 3.467

3.  Refinement of axonal conduction and myelination in the mouse optic nerve indicate an extended period of postnatal developmental plasticity.

Authors:  Annika Balraj; Cheryl Clarkson-Paredes; Ahdeah Pajoohesh-Ganji; Matthew W Kay; David Mendelowitz; Robert H Miller
Journal:  Dev Neurobiol       Date:  2022-04-27       Impact factor: 3.102

4.  Spontaneous optic nerve compression in the osteopetrotic (op/op) mouse: a novel model of myelination failure.

Authors:  Yoichi Kondo; Jenna M Ramaker; Abigail B Radcliff; Simona Baldassari; Joshua A Mayer; James N Ver Hoeve; Chuan-Li Zhang; Shing-Yan Chiu; Raymond J Colello; Ian D Duncan
Journal:  J Neurosci       Date:  2013-02-20       Impact factor: 6.167

Review 5.  Neuroprotection by central nervous system remyelination: Molecular, cellular, and functional considerations.

Authors:  Dylan Verden; Wendy B Macklin
Journal:  J Neurosci Res       Date:  2016-09-12       Impact factor: 4.433

6.  The circadian clock gene Bmal1 is required to control the timing of retinal neurogenesis and lamination of Müller glia in the mouse retina.

Authors:  Onkar B Sawant; Vijay K Jidigam; Rebecca D Fuller; Olivia F Zucaro; Cristel Kpegba; Minzhong Yu; Neal S Peachey; Sujata Rao
Journal:  FASEB J       Date:  2019-04-19       Impact factor: 5.834

7.  Carnosic acid slows photoreceptor degeneration in the Pde6b(rd10) mouse model of retinitis pigmentosa.

Authors:  Kai Kang; Matthew J Tarchick; Xiaoshan Yu; Craig Beight; Ping Bu; Minzhong Yu
Journal:  Sci Rep       Date:  2016-03-10       Impact factor: 4.379

8.  Myelination of Neuronal Cell Bodies when Myelin Supply Exceeds Axonal Demand.

Authors:  Rafael G Almeida; Simon Pan; Katy L H Cole; Jill M Williamson; Jason J Early; Tim Czopka; Anna Klingseisen; Jonah R Chan; David A Lyons
Journal:  Curr Biol       Date:  2018-04-05       Impact factor: 10.834

9.  Lutein and Zeaxanthin Isomers Reduce Photoreceptor Degeneration in the Pde6b rd10 Mouse Model of Retinitis Pigmentosa.

Authors:  Minzhong Yu; Weiming Yan; Craig Beight
Journal:  Biomed Res Int       Date:  2018-12-17       Impact factor: 3.411

10.  Alleviation of extensive visual pathway dysfunction by a remyelinating drug in a chronic mouse model of multiple sclerosis.

Authors:  Maria T Sekyi; Kelli Lauderdale; Kelley C Atkinson; Batis Golestany; Hawra Karim; Micah Feri; Joselyn S Soto; Cobi Diaz; Sung Hoon Kim; Marianne Cilluffo; Steven Nusinowitz; John A Katzenellenbogen; Seema K Tiwari-Woodruff
Journal:  Brain Pathol       Date:  2021-01-29       Impact factor: 6.508

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.